Table 1.

Demographics and baseline disease characteristics by treatment-group completer population in patients with DAS28-ESR or SDAI data available at 1 year.

CharacteristicsETN + MTX, n = 213MTX, n = 178Total, N = 391
Demographic
  Age, yrs50.9 (14.4)52.8 (12.8)51.8 (13.7)
  Female, n (%)157 (74)126 (71)283 (72)
  White, n (%)185 (87)157 (88)342 (87)
  Previous DMARD, n (%)34 (16)43 (24)77 (20)
  Previous corticosteroids, n (%)104 (49)85 (48)189 (48)
  Previous NSAID, n (%)160 (75)140 (79)300 (77)
At baseline, mean (SD)
  Disease duration, mos8.6 (5.6)8.5 (5.3)8.6 (5.5)
  DAS28-ESR6.4 (1.0)6.5 (1.0)6.5 (1.0)
  SDAI41.9 (15.0)43.3 (14.4)42.6 (14.7)
  Tender joint count, 71 joints23.5 (13.7)24.1 (14.0)23.7 (13.8)
  Swollen joint count, 68 joints16.8 (10.4)17.5 (9.6)17.1 (10.0)
  CRP, mg/l37.8 (39.8)37.8 (33.7)37.8 (37.1)
  ESR, mm/h47.4 (24.5)49.7 (24.6)48.5 (24.5)
  • CRP: C-reactive protein; DAS28-ESR: Disease Activity Score-28 joints calculated by erythrocyte sedimentation rate; DMARD: disease-modifying antirheumatic drugs; ETN: etanercept; MTX: methotrexate; NSAID: nonsteroidal antiinflammatory drugs; SDAI: Simplified Disease Activity Index.